Search

Your search keyword '"Ohyashiki,Kazuma"' showing total 1,594 results

Search Constraints

Start Over You searched for: Author "Ohyashiki,Kazuma" Remove constraint Author: "Ohyashiki,Kazuma"
1,594 results on '"Ohyashiki,Kazuma"'

Search Results

1. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms

3. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

5. Treatment-free remission after first-line dasatinib treatment in patients with chronic myeloid leukemia in the chronic phase: the D-NewS Study of the Kanto CML Study Group

6. Clonal evolution and clinical implications of genetic abnormalities in blastic transformation of chronic myeloid leukaemia

10. Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial

11. Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study

17. Long‐term follow‐up after R‐High CHOP / CHASER / LEED with Auto‐PBSCT in untreated mantle cell lymphoma—Final analysis of JCOG0406

18. Supplementary Table from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia

19. Supplementary Figure from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia

20. Data from Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia

21. Abstract 6168: Implementation and adoption of a web tool to support precision diagnostic and treatment decisions for patient with myelodysplastic syndromes

22. Postazacitidine clone size predicts long-term outcome of patients with myelodysplastic syndromes and related myeloid neoplasms

23. Switching to nilotinib in patients with chronic myeloid leukemia in chronic phase with molecular suboptimal response to frontline imatinib: SENSOR final results and BIM polymorphism substudy

27. Data from Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome

28. Supplementary Data 4 from Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome

29. Supplementary Table 1 from Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome

30. Supplementary Figure 1-11 from Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome

31. Supplementary Data 2 from Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome

32. Supplementary Data 1 from Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome

33. Supplementary Table 2 from Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome

34. Supplementary Data 3 from Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic Syndrome

35. Germ line DDX41 mutations define a unique subtype of myeloid neoplasms

36. Cefozopran, meropenem, or imipenem–cilastatin compared with cefepime as empirical therapy in febrile neutropenic adult patients: A multicenter prospective randomized trial

37. Ponatinib in Japanese patients with Philadelphia chromosome-positive leukemia, a phase 1/2 study

41. Germline Risks and Clinical Impacts of DDX41 Mutations in Myeloid Malignancies

42. Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)

43. Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan

45. Amplified EPOR/JAK2 Genes Define a Unique Subtype of Acute Erythroid Leukemia

46. Clinical efficacy and safety of arbekacin sulfate in patients with MRSA sepsis or pneumonia: a multi-institutional study

Catalog

Books, media, physical & digital resources